Aspirin-free P2Y12 inhibitor monotherapy immediately after percutaneous coronary intervention: A systematic review.

ABSTRACT:

Background

A modified antiplatelet therapy approach after percutaneous coronary intervention (PCI), specifically reducing dual antiplatelet therapy (DAPT) duration and transitioning to P2Y12 inhibitor monotherapy, may offer advantages in terms of bleeding risk reduction. However, the impact of initiating aspirin-free P2Y12 inhibitor monotherapy immediately after PCI is not yet fully understood.

Methods

We systematically searched the PubMed and Embase databases until January 2024 for studies that examined the use of P2Y12 inhibitor monotherapy as a treatment approach without initial DAPT following PCI.

Results

Four single-arm pilot prospective studies and 1 randomized controlled trial were included. In acute coronary syndrome patients with P2Y12 monotherapy following a

SUBMITTER: Yu S 

PROVIDER: S-EPMC11336810 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature